Evonik Evonik

X

Find 6-Thio-2-Deoxyguanosine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

6-Thio-2-Deoxyguanosine
Also known as: 789-61-7, 6-thio-dg, Tgdr, Thioguanine deoxyriboside, 6-thio-2'-deoxyguanosine, 2'-deoxy-6-thioguanosine
Molecular Formula
C10H13N5O3S
Molecular Weight
283.31  g/mol
InChI Key
SCVJRXQHFJXZFZ-KVQBGUIXSA-N
FDA UNII
KR0RFB46DF

Beta-Thioguanine Deoxyriboside is a thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication. This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo. Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)
1 2D Structure

6-Thio-2-Deoxyguanosine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purine-6-thione
2.1.2 InChI
InChI=1S/C10H13N5O3S/c11-10-13-8-7(9(19)14-10)12-3-15(8)6-1-4(17)5(2-16)18-6/h3-6,16-17H,1-2H2,(H3,11,13,14,19)/t4-,5+,6+/m0/s1
2.1.3 InChI Key
SCVJRXQHFJXZFZ-KVQBGUIXSA-N
2.1.4 Canonical SMILES
C1C(C(OC1N2C=NC3=C2NC(=NC3=S)N)CO)O
2.1.5 Isomeric SMILES
C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=S)N)CO)O
2.2 Other Identifiers
2.2.1 UNII
KR0RFB46DF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2'-deoxy-6-thioguanosine

2. Beta-2'-deoxythioguanosine

3. Beta-2'-deoxythioguanosine Mono-hydrate

4. Beta-thioguanine Deoxyriboside

2.3.2 Depositor-Supplied Synonyms

1. 789-61-7

2. 6-thio-dg

3. Tgdr

4. Thioguanine Deoxyriboside

5. 6-thio-2'-deoxyguanosine

6. 2'-deoxy-6-thioguanosine

7. Beta-2'-deoxythioguanosine

8. 2'-desoxy-6-thioguanosine

9. 6-mercaptoguaninedeoxyriboside

10. Kr0rfb46df

11. Beta-thioguanidine Deoxyriboside

12. Beta-thioguanine Deoxyriboside

13. 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione

14. Beta-2'-deoxy-6-thioguanosine Monohydrate

15. Guanosine, 2'-deoxy-6-thio-

16. B-tgdr

17. 2'deoxy-6-thioguanosine

18. Thio

19. 2'-deoxy-6-thio Guanosine

20. Beta-2'-deoxythiol Guanosine

21. Ccris 195

22. Nsc71261

23. Nsc-71261

24. Thioguanine Deoxyriboside (van)

25. Thiodeoxyguanosine

26. Hsdb 7074

27. Beta-tgdr

28. 2-amino-9-(2-deoxy-beta-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purine-6-thione

29. Nci-c01581

30. Thioguanine 9betad-2'-deoxyriboside

31. Brn 1224220

32. 6-thio-dg;

33. A-tgdr

34. Unii-kr0rfb46df

35. Schembl531274

36. Beta-thioguanosine Deoxyriboside

37. Schembl9634767

38. Chembl3250476

39. Dtxsid4021345

40. Mfcd00672275

41. S7757

42. Zinc17969618

43. Ccg-267279

44. Ac-32335

45. Hy-18762

46. Cs-0014289

47. 6-thio-2 Inverted Exclamation Marka-deoxyguanosine

48. 2-amino-9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-mercaptopurine

49. 2-amino-9-(2-deoxy-.beta.-d-erythropentofuranosyl)-9h-purine-6(1h)-thione

50. 9h-purine-6(1h)-thione, 2-amino-9-(2-deoxy-beta-d-erythro-pentofuranosyl)-

51. 2-amino-9-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purine-6(9h)-thione

52. 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1h-purine-6-thione

53. 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purine-6-thione

54. 30241-92-0

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 283.31 g/mol
Molecular Formula C10H13N5O3S
XLogP3-0.8
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass283.07391047 g/mol
Monoisotopic Mass283.07391047 g/mol
Topological Polar Surface Area150 Ų
Heavy Atom Count19
Formal Charge0
Complexity420
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

STUDIES SUGGEST THAT BETA-TGDR IS A LATENT FORM OF TG. SINCE RESISTANCE TO ANTILEUKEMIC AGENT 6-THIOGUANINE INEVITABLY DEVELOPS IN ANIMAL TUMORS, THIS NEW AGENT BETA-TGDR IS OF POTENTIAL CLINICAL USE.

LU K ET AL; PHARMACOKINETICS AND METABOLISM OF BETA-2'-DEOXYTHIOGUANOSINE AND 6-THIOGUANINE IN MAN; CANCER CHEMOTHER PHARMACOL 8 (1): 119-23 (1982)


5 Pharmacology and Biochemistry
5.1 Metabolism/Metabolites

THE PHARMACOKINETICS OF RADIOLABELED 6-THIOGUANINE (TG) WERE COMPARED WITH THAT OF BETA-2'-DEOXYTHIOGUANOSINE (BETA-TGDR) AFTER IV ADMIN. URINARY EXCRETION OF THE RADIOLABEL WAS 75% OF THE DOSE 24 HR AFTER ADMIN. BOTH THIOPURINES WERE RAPIDLY & EXTENSIVELY DEGRADED & EXCRETED AS 6-THIOXANTHINE, INORGANIC SULFATE, S-METHYL-6-THIOXANTHINE, & 6-THIOURIC ACID IN ADDITION TO OTHER PRODUCTS. SMALL AMOUNTS OF UNCHANGED DRUG WERE ALSO EXCRETED. STUDIES SUGGEST THAT BETA-TGDR IS A LATENT FORM OF TG. SINCE RESISTANCE TO ANTILEUKEMIC AGENT 6-THIOGUANINE INEVITABLY DEVELOPS IN ANIMAL TUMORS, THIS NEW AGENT BETA-TGDR IS OF POTENTIAL CLINICAL USE.

LU K ET AL; PHARMACOKINETICS AND METABOLISM OF BETA-2'-DEOXYTHIOGUANOSINE AND 6-THIOGUANINE IN MAN; CANCER CHEMOTHER PHARMACOL 8 (1): 119-23 (1982)


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY